Combined clearance of the navigation and drug delivery technologies enables Canadian neurosurgery centers to leverage the Company's flagship image-guidance workflow and advances ClearPoint Neuro's ove
ClearPoint Neuro, Inc. (CLPT) Q4 2025 Earnings Call Transcript
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.2 per share a year ago.
Record Revenue and IRRAS Holdings Acquisition Highlight the Company's 'Fast. Forward.' Strategy SOLANA BEACH, CA / ACCESS Newswire / March 17, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company
ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc
SOLANA BEACH, CA / ACCESS Newswire / March 6, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the b
ClearPoint secures EU MDR certification for ClearPoint Navigation Software 3.0.2, expanding precision-guided surgery access across MRI suites and operating rooms.

ClearPoint Neuro: From Validation To Scale

04:47am, Tuesday, 27'th Jan 2026
ClearPoint Neuro is positioned for robust growth in 2026, driven by IRRAS, the PRISM 1.5T system clearance, and the company's new CRO facility. While the immediate future of uniQure's AMT-130 remains
ClearPoint Neuro, Inc. (NASDAQ: CLPT) on Friday said it received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2.
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigati
The Company Achieved 20% Comparable Sales Growth in the Fourth Quarter of 2025 at $10.4 Million SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 12, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (th
Sartorius (OTCMKTS:SARTF - Get Free Report) and ClearPoint Neuro (NASDAQ: CLPT - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based
Investment strategist Shay Boloor has outlined ten sub-$10 billion market-cap companies he believes are positioned to benefit from powerful long-term trends heading into 2026.

ClearPoint Neuro Completes Acquisition of IRRAS

05:00pm, Thursday, 20'th Nov 2025
Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation SOLANA BEACH, CALIFORNIA / ACCESS Newswire
ClearPoint Neuro, Inc. ( CLPT ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Joseph Burnett - President, CEO & Director Danilo D'Alessandro - Chief Financial Officer Confere
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE